phase 1b

Studies associated with:
Division Study Number Title Investigator(s) Release Date
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., Theresa Winhusen, Ph.D.
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D.
DTMC NIDA-CTO-0004 Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline Thomas F. Newton, M.D.
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D.
DTMC NIDA-CTO-0002 Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D.
DTMC NIDA-CPU-0016 Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) Eugene Somoza, M.D.